S&P 500
7,633.20
+0.31%
Dow Jones
53,893.00
+1.14%
Nasdaq 100
29,106.20
+0.99%
Russell 2000
2,995.41
+0.37%
FTSE 100
10,904.40
+0.20%
Nikkei 225
64,309.90
+1.28%

Health and Healthcare

J&J, Pfizer Halt Development of Alzheimer’s Drug

Photo of 247sam
By 247sam Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Invalid Image
Johnson & Johnson Inc. (NYSE: JNJ) and Pfizer Inc. (NYSE: PFE) both announced they are stopping development of a drug to treat patients with mild to moderate Alzheimer’s after the drug failed a second clinical trial.

The companies both noted the drug, bapineuzumab, did not improve the condition of Alzheimer’s patients compared to a placebo.

Johnson & Johnson will take a $300 million to $400 million charge in the third quarter.

Shares of Pfizer are down 2.51% in after-hours trading. Shares of Johnson & Johnson are up 0.21%.

Samuel Weigley

Contact [email protected] for any questions or corrections.

Follow 24/7 Wall St. on Google
Photo of 247sam
About the Author 247sam →

Continue Reading

The List of Failed Alzheimer’s Drug Treatments Keeps Growing
Jon C. Ogg |

The List of Failed Alzheimer’s Drug Treatments Keeps Growing

If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech…

Paul Ausick |

Pfizer’s Alzheimer’s Drug Fails Trial

A new treatment for Alzheimer’s disease from Pfizer Inc. (NYSE: PFE) and partner Elan Corp. plc (NYSE: ELN) has failed…

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure
Jon C. Ogg |

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure

It's an impressive day when two IPOs are well received when drug-selling revenues are unlikely for quite some time, and…

Jon C. Ogg |

BioHealth Daily: Forgetting Alzheimers (PRAN, PFE, NVS, FRX)

It’s the BioHeath Daily for key developments in drugs, biotech, and medical developments.  Prana Biotechnology Ltd. (NASDAQ: PRAN) is often…

Paul Ausick |

Alzheimer’s Drug Shows Some Success (LLY, PFE, ELN)

Drugmaker Eli Lilly & Co. (NYSE: LLY) announced this morning that the company’s solanezumab treatment for Alzheimer’s disease failed to…

Douglas A. McIntyre |

Barron’s Alzheimer’s Article Only Scratches the Surface

Stock Tickers: WYE, NRMX, ELN, NVS, PFE, LLY, JNJ, AZN, TRGT, SNH, SRZ, BKD, ALC, HCR, ESC, MYGN, FRX, NYMX,…

The 2016 Bullish and Bearish Case for Pfizer, Merck, Johnson & Johnson
Chris Lange |

The 2016 Bullish and Bearish Case for Pfizer, Merck, Johnson & Johnson

24/7 Wall Street has evaluated three major Dow components in the pharmaceutical industry and presented the bullish and bearish case…

Jon C. Ogg |

Elan’s Spin-Off Creates Buyout Hopes (ELN, BIIB, ALKS, PFE)

Elan Corporation, plc (NYSE: ELN) may be surging on news that it is going to spin off its drug research unit,…

Douglas A. McIntyre |

Major Biotech Movers (AGEN, CEGE, ENCY, IDMI, IMCL, ONXX, PFE, NTII, OXGN, PSDV, SIRT)

Antigenics Inc.  (NASDAQ: AGEN) A study for Cancer vaccine, Oncophage, for the treatment of metastatic melanoma showed mixed results this…

Top Gaining Stocks

Airbnb
ABNB • Vol: 15,821,180
Microchip Technology
MCHP • Vol: 18,798,580
Palantir
PLTR • Vol: 76,081,132
Moderna
MRNA • Vol: 6,798,796
Axon Enterprise
AXON • Vol: 1,570,941

Top Losing Stocks

Trade Desk
TTD • Vol: 132,838,464
Coterra Energy
CTRA • Vol: 73,319,495
Akamai
AKAM • Vol: 7,977,628
Zoetis
ZTS • Vol: 12,738,742
ResMed
RMD • Vol: 3,773,864